INTRODUCTION
Colorectal cancer (CRC) is the third most common cause of cancer and the second most common cause of death in the United States. As the development of CRC is a multistep process, pharmacologic chemoprevention has potential implications for primary and secondary prevention (1) . During the past decade, statins have consistently been the most widely prescribed drug category in the United States (2) , and experimental studies indicate a potential cancer prevention e ect for adenocarcinoma cells (4, 5) or in inducing apopotosis and inhibiting the metastatic potential of colon cancer cell lines (6, 7) .
In humans, secondary analyses from large randomized controlled studies indicate a possible statin-related reduction in overall cancer mortality, but there is insu cient data from these trials to allow speci c examination of individual cancer types (8, 9) . e available epidemiological data for CRC are conicting with some studies reporting no signi cant association (10 -14) , and a few other studies reporting moderate reductions in the risk of CRC in statin users (15 -17) . Only ve of these studies have speci cally examined CRC as a primary outcome (10, 12, 15, 16, 18) . Some of these studies were limited by short exposure time, recall bias (10, 15) , and insu cient accounting for confounders or e ect modi ers because of inadequate power (16) . In addition, the association of statins with highrisk populations (i.e., African Americans, patients with polyps) has not been well characterized in these studies.
Given the widespread use of statins (19) and the high prevalence of CRC, their potential association is important to examine further. erefore, we sought to examine the risk of CRC associated with the use of statins in a pharmacoepidemiological study using a matched case -control design nested within a well-characterized cohort of patients with diabetes. Furthermore, we examined the potential determinants of association including type, dose, and duration of statin use, and its interaction with other known potential determinants of CRC.
METHODS
is study was approved by the Institutional Review Boards of Baylor College of Medicine and the Michael E. DeBakey VA Medical Center in Houston, TX.
Data source
We conducted a nested case -control study within a large cohort of patients with diabetes mellitus (DM), identi ed between calendar year (CY) 1997 and 2002 in the national databases of the Department of Veterans A airs (VA). ese databases included the patient treatment le (PTF), outpatient clinic (OPC) le, pharmacy bene ts management (PBM) le, and bene ciary identi cation records locator system (BIRLS) death le. e PTF contains demographic data, date of admission, and discharge, and up to 10 discharge diagnoses (by the International Classi cation of Diseases, 9th Revision, Clinical Modi cation (ICD-9) codes) for all hospitalizations in over 150 VA hospitals in the United States (20) . e OPC le contains similar data for all outpatient encounters. In the OPC and PTF, we identi ed patients with ICD-9 codes for DM (250.0 -250.9, 357.2, 362.0, and 366.41). We employed an additional measure to de ne the DM cohort by searching the VA PBM les (CY 1999 (CY -2002 for prescriptions for oral diabetes medications (HS502), insulin (HS501), or blood glucose monitoring supplies. Each patient was assigned an entry date into the DM cohort based on their earliest qualifying inpatient or outpatient encounter. e VA DM cohort was linked with Medicare claims les (CY 1999 (CY -2002 to maximize the probability of capturing health care encounters among dual VA -Medicare users (21) .
Study population
We excluded from the sampling frame patients who had a diagnosis of cancers of the pancreas (157.0 -157.9), stomach (151.0 -151.9), lung (162.0 -162.9), esophagus (150.0 -150.9), liver (155.0, 155.2), and breast (174.0 -175.0, 175.9) before index CRC diagnosis date. To maximize the completeness of exposure and risk factor information, cases were excluded if they had any Health Maintenance Organization (HMO) enrollment or had enrollment in Medicare for less than 75 % of the time they were eligible. erefore, all patients were dually enrolled in both the VA and Medicare healthcare systems.
Case subjects were selected from patients with incident CRC de ned by ICD-9 codes, which included colon or rectal cancer (153.0 -153. Control subjects were eligible patients who remained at risk at the date of the CRC diagnosis for the case. Each case was matched with up to four controls on sex and year of birth ( ± 1 year), and sampled on incidence density, where matching was performed for both enrollment date in the diabetic cohort ( ± 30 days) as well as CRC diagnosis date. Controls were selected randomly with replacement, such as one subject could be a control for more than one case, and any one control could become a case later by developing CRC.
Exposure
Statin exposure was obtained from lled outpatient prescriptions between 1 January 1999 and the date of CRC diagnosis (or corresponding date for controls). We collected the dates of lled or re lled prescriptions and the daily dose per prescription. In the case of overlapping prescriptions, exposure days were calculated as the sum of the day ' s supply of prescriptions if the overlap was ≤ 30 days. If the overlap was > 30 days, we only considered the more recent prescription, and assumed that the new prescription had replaced the previous one. We collected similar prescription information on nonstatin lipidlowering medications (cholestyramine, colesevelam, colestipol, ezetimibe, and niacin), and triglyceride-lowering medications (clo brate, feno brate, and gem brozil).
Statistical analyses
Cases and controls were compared with regard to di erences in covariate distribution using 2 -tests for categorical variables and t -tests for continuous variables. Odds ratios (ORs) as estimates of the relative risk for CRC, de ned as combined colon or rectal cancer, associated with statin use, and 95 % con dence intervals (CIs) were estimated using conditional logistic regression. In addition to matching variables, adjustment was carried out for potential confounding factors, including in ammatory bowel disease (555 and 556), severity of diabetes (retinopathy (250.5 and 362.0), nephropathy (250.4), neuropathy (250.6, 357.2)), liver disease (570.X-573.X, 794.8), and cholecystectomy (51.21 -51.24, and CPT codes 47600, 47605, 47610, 47612, 47620, 49310, and 49311). ese variables were de ned based on the presence of one inpatient or two outpatient ICD-9 codes before CRC index. We ascertained colorectal evaluation by imaging, endoscopy, or fecal occult blood testing, excluding those recorded within 6 months of CRC index date. Potential e ect modi ers that were examined in strati ed analyses included the presence of previous colorectal polyps, cancer site (colon vs. rectal), race, and age. We also ascertained lled prescriptions before index date for diabetes medications (insulin, sulfonylurea, thioglitazone, or other diabetes medication), aspirin, and nonsteroidal anti-in ammatory drugs (NSAIDs). e distribution of at least one lled prescription of exposures listed above was compared between cases and controls. In a separate analysis, we excluded statin prescriptions recorded in the year preceding the index date, to reduce the possibility of confounding by indication. To examine duration -response associations, we evaluated the e ect of cumulative duration of lled prescriptions categorized as 0 -180, 181 -360, 361 -540, 541 -720, and >720 days.
e cumulative dose for simvastatin was calculated as the total duration for lled prescriptions multiplied by dosage and summed across all prescriptions. e average daily dose was calculated as the cumulative dose divided by the total number of days used. We compared the distribution of dose quartiles as well as a variable indicating ≥ 1.5 × mean cumulative dose (vs. < 1.5 × mean).
Finally, to examine potential e ect modi ers, we conducted analyses strati ed by the presence of previous colorectal polyps (ICD-9 codes: 211.3, 211.4, 569.0, and V12.72), cancer site as delineated by a colon cancer alone that excluded rectal cancer (ICD-9 codes: 153.0 -153.9, and 230.3), rectal cancer (ICD-9 codes: 154.0, 154.1, 154.8, and 230.4), race (African American), and age (65 years and older).
RESULTS
e cohort consisted of 763,807 veterans diagnosed with DM during CY 1997 -2002. ere were 6,080 CRC cases and 24,320 controls who ful led the inclusion and exclusion criteria. Given the incidence density sampling, the case -control ratio was close, but not exactly 1 -4; 672 unique controls were each matched to two di erent cases, 13 controls were each matched to three di erent cases, and 97 controls became cases at a later time. us, the nal analysis was conducted on 6,080 cases and 24,320 controls. Table 1 shows the demographic features of cases and controls. e mean age of patients was 74 years and the majority were Caucasian (84 % ) and male (99 % ) with no di erence between cases and controls. e mean duration between date of entry into DM cohort and date of CRC index was 842 days.
Filled prescriptions for any statin were documented in 51 % of the study population, and simvastatin comprised the majority (87 % ) of statin use.
e mean duration of statin use was statistically shorter in cases than controls before CRC index (274 and 296 days, respectively ( P < 0.0001)). Table 2 shows the comparisons between controls and cases with regard to potential confounders and e ect modi ers. As expected, cases were more likely than controls to have a history of colorectal polyps and in ammatory bowel disease. Controls had signi cantly more colorectal evaluation by imaging, endoscopy, or fecal occult blood testing. Cases were also more likely than controls to have markers of serious or prolonged diabetes, including diabetic nephropathy or sulfonylurea-lled prescriptions. Finally, cases were signicantly less likely to have lled aspirin / NSAID prescriptions. e presence of a lled prescription for any statin was inversely associated with CRC risk in the unadjusted regression model (OR: 0.88; 95 % CI: 0.83 -0.93; Table 3 ). Similar risk reductions were observed when we excluded lled statin prescriptions in the 1 year before the CRC index date. e inverse association was attenuated but remained signi cant (OR: 0.91; 95 % CI: 0.86 -0.96) a er adjusting for in ammatory bowel disease, diabetic nephropathy, colorectal evaluation before CRC diagnosis, cholecystectomy, liver disease, and lled prescriptions of sulfonylurea, aspirin, or NSAIDs. Adjustment for these variables was performed because they were signi cantly associated with CRC in unadjusted analyses ( Table 2 ). Regular use of statin as indicated by lled prescription greater than 80 % of e association between statins and CRC was modi ed by the presence of previous colorectal polyps as de ned by ICD-9 codes. ere was no consistent decrease in CRC risk in the subgroup with previous polyps ( Table 3 ) , whereas a 14 % risk reduction was noted with any statin prescription in the subgroup without known polyps. is reduced risk persisted in models adjusted for in ammatory bowel disease, diabetic nephropathy, colorectal evaluation, cholecystectomy, lled prescriptions of sulfonylyurea, NSAIDs, and liver disease. Race was also a potential e ect modi er; there was no signi cant association between statins and CRC for any duration or dose duration of statins in African Americans (data not shown).
We examined the e ect of cumulative duration of statin prescriptions. We found no consistent duration -response relationship, with both short ( < 6 months) and long duration (>24 months) signi cantly associated with decreased CRC risk, and the other periods not signi cantly associated with CRC risk ( Table 4 ) . ere was also no duration -response relationship (data not shown) in an analysis that excluded lled statin prescriptions in the 1 year before CRC diagnosis. Similar ndings were noted for simvastatin (data not shown).
To examine the possibility of a medication class e ect, we analyzed the data for simvastatin and observed similar results in both direction and magnitude as those for any statin ( Table 5 ). Simvastatin was associated with a small but signi cant reduction in CRC risk in unadjusted and adjusted models but with no duration -response relationship. On the other hand, nonstatin lipid-and triglyceride-lowering medications ( Table 6 ) showed no association with CRC in unadjusted and adjusted conditional logistic regression models as well as in analysis strati ed by the presence of previous polyps. 
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In another analysis restricted to patients with rectal cancer alone (1,417 cases and 5,668 controls), no signi cant risk reduction was noted with any statin ( Table 7 ) or simvastatin in the unadjusted or adjusted models (data not shown). However, the power of the analysis was limited due to small numbers.
DISCUSSION
is study indicates that statin use may be associated with a small but signi cant reduction in the risk of CRC in patients with diabetes.
is risk reduction was seen with statins as a group, as well as simvastatin-only lled prescriptions.
In an analysis limited to patients aged 65 years and older, similar risk reductions to the whole population were noted for However, it was not seen with triglyceride-or nonstatin cholesterol-lowering medications. e risk reduction observed may be more important for colon cancer, as there was no signi cant risk reduction with statin use when analyzing rectal cancer separately.
Furthermore, the possible statin e ect was limited to subgroups of patients with no previous colorectal polyps, aged 65 years and older, and Caucasians. However, there was no consistent signi cant dose or duration -response relationship. Of note, the signi cant risk reduction observed among the relatively few patients exposed to statin use >24 months suggests that longer duration of exposure may be necessary for the assessment of a signi cant reduction of CRC with statin use. is is in agreement with a previous case -control study that found a reduced risk of CRC associated with statins, speci cally simvastatin, especially with use greater than 5 years (OR: 0.53; 95 % CI: 0.38 -0.74) (15) . However, another population-based study from Germany indicated a 64 % CRC risk reduction occuring within 1 -4 years of statin use, with no further risk reduction beyond 5 years (16) . Neither study characterized dose or duration of statins in detail, and both studies de ned statin use by recall. Our results, however, con ict with a recent case -control study (1,809 cases and 1,809 controls) that found no signi cant Results of conditional logistic regression models. a Adjusted for the following variables: infl ammatory bowel disease, diabetic nephropathy, colorectal evaluation, cholecystectomy, sulfonylurea prescription, nonsteroidal anti-infl ammatory drug prescription, and liver disease. Given the nature of the administrative data, we were not able to capture all potential confounding variables for CRC risk, including alcohol or tobacco use, family history of colon cancer, dietary or exercise history, and socioeconomic status. However, the study dealt with a mostly low-income group (veterans who use VA services), hence we do not expect major variations in socioeconomic status, as re ected by income and education.
Moreover, although it is reasonable to assume that fecal occult blood testing (FOBT) was performed for CRC screening, we were not able to determine the purpose of the imaging or colonoscopy as to screening, surveillance, or diagnosis.
Furthermore, incident CRC diagnosis was based on rst time appearance of ICD-9 codes for CRC during 1999 -2002. e use of ICD-9 codes can be erroneous, but in this study, we performed a chart review in a sample of cases and found a PPV of 83 % for CRC ICD-9 codes. Also, an earlier Spanish study validated ICD-9 codes for CRC and showed a sensitivity of 80 % and a positive predictive value of 75 % of hospital administrative data when compared with a cancer registry as a gold standard (33) . Exposure was based on lled statin prescriptions and may not accurately capture intake. e potential for missed statin prescriptions received in non-VA facilities may underestimate our ndings; however, these errors are likely to occur at random. In addition, we have previously shown that among VA and Medicare dual users, most veterans use VA for their pharmacy services for the majority of their medications (22) . Finally, like other observational studies, residual confounding cannot be completely excluded. For example, statin use might be associated with weight reduction or better diabetic control, and these other measures might be related to CRC risk.
ere are several strengths to our study, including large samples with a relatively long duration of potential exposure to statins. We had virtually complete capture of VA pharmacy data through the VA -PBM records, and CRC through the linked VA -Medicare records. We also had the additional advantage of evaluating large numbers of patients, underrepresented in other studies, with a substantial African American and elderly patient population. We performed several sensitivity analyses of exposure within subgroups to examine the robustness of ndings. Finally, our results con rmed the earlier ndings indicating protective bene t of NSAID use and CRC screendecreased risk of CRC associated with regular statin use (OR: 0.92; 95 % CI: 0.78 -1.1) (10) . In that study, atorvastatin was the most commonly used statin. e disparate results between simvastatin and atorvastatin may arise because individual statins have shown di erences in speci cities for HMG-CoA reductase, metabolism, and volumes of distribution (22, 21) . In another population-based nested case -control study (5, 686 cases and 24,982 controls) from the United Kingdom, there was no signi cant risk reduction in CRC with any statin use; however, similar to our study, a 17 % risk reduction ( P = 0.01) was shown with simvastatin use (18) . It is unclear whether the type of statin plays a role in the potential e ect of statins in CRC risk, and this should be explored further.
ere were no signi cant risk reductions in groups with high risk for CRC, such as African Americans and patients with previous coloerectal polyps. Although relatively limited power might have played a role in these subgroups, it is possible that the modest preventive action of statins is unlikely to be prominent in the presence of other strong risk factors. Multiple studies have shown increased incidence and mortality rates from CRC in the African American population (23, 24) and in patients with previous colorectal polyps (25) with high prevalence for dyslipidemia in both of these populations (26, 27) . Our subgroup analysis of patients with known previous colorectal polyps contained 2,078 cases and 4,252 controls. An earlier study of 2,638 patients found no bene t for preventing the recurrence of colorectal adenomas, multiple adenomas, or advanced adenomas with over 4 years of statin use (28) . It is possible that polypectomy lowers the risk to a large extent, obscuring any additional advantage of statins. Our study de ned previous colorectal polyps by ICD-9 codes and lacked pathological con rmation. It is possible that polyps that do not pose a higher risk for CRC (e.g., isolated hyperplastic polyps) were included. Irrespective of the nature of the polyp, the presence of these codes was more common in cases than controls (34 vs. 17 % ). Finally, although the observed lack of association between statins and rectal cancer could be a true e ect, the power of the study was relatively limited, especially for examining long duration of statin use.
e ndings need to be interpreted within other limitations of the study. Several di erences between cases and controls were modest although, given the large sample size statistically signi cant. However, we had a focused hypothesis regarding the possible e ect of statins, and thus we did not adjust for multiple testing. In addition, the study was limited to mostly male veterans with diabetes, and may not be generalizable to women, nonveterans, or patients without diabetes. e choice for the diabetes cohort for this study was made both for convenience, given the availability of this well-characterized cohort, as well as for the potential of better detection of small e ects. Diabetes has been suggested as a modest risk factor for colorectal polyps as well as CRC (29, 30) . erefore, it is possible that it was easier to show bene t in this study owing to the generally elevated risk in patients with diabetes. Earlier studies evaluating the association between statins and cancer in patients with diabetes included
